Pub Date : 2023-03-01DOI: 10.13189/cor.2023.080101
G. Sonawane, Santosh Singh, Kajal Pansare, Chandrashekhar Patil, Deepak B. Somavanshi
{"title":"Construction and Analysis of Adverse Reaction Prediction Model for Patients with Hepatocellular Carcinoma Undergoing Radiotherapy and Chemotherapy Based on Image Detection","authors":"G. Sonawane, Santosh Singh, Kajal Pansare, Chandrashekhar Patil, Deepak B. Somavanshi","doi":"10.13189/cor.2023.080101","DOIUrl":"https://doi.org/10.13189/cor.2023.080101","url":null,"abstract":"","PeriodicalId":15189,"journal":{"name":"Journal of Cancer Research and Therapeutic Oncology","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78601916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-01DOI: 10.13189/cor.2022.080101
E. George, Anjali Ambrose, Shaji George, J. Aaron
{"title":"To Assess the Efficacy Outcomes of Patients Undergoing Androgen Deprivation Therapy in a Tertiary Care Hospital: A Retrospective Study","authors":"E. George, Anjali Ambrose, Shaji George, J. Aaron","doi":"10.13189/cor.2022.080101","DOIUrl":"https://doi.org/10.13189/cor.2022.080101","url":null,"abstract":"","PeriodicalId":15189,"journal":{"name":"Journal of Cancer Research and Therapeutic Oncology","volume":"33 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86858462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.17303/jcrto.2022.10.102
S. Guarino
{"title":"Ribociclib Improves Clinical Outcomes in Breast Cancer Brain Metastases: A Case Report","authors":"S. Guarino","doi":"10.17303/jcrto.2022.10.102","DOIUrl":"https://doi.org/10.17303/jcrto.2022.10.102","url":null,"abstract":"","PeriodicalId":15189,"journal":{"name":"Journal of Cancer Research and Therapeutic Oncology","volume":"49 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90865754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.17303/jcrto.2022.10.101
K. Omabe
{"title":"Translationally Controlled Tumor Protein: A Key Target to Abrogate DNA Repair and Therapeutic Resistance in Cancer","authors":"K. Omabe","doi":"10.17303/jcrto.2022.10.101","DOIUrl":"https://doi.org/10.17303/jcrto.2022.10.101","url":null,"abstract":"","PeriodicalId":15189,"journal":{"name":"Journal of Cancer Research and Therapeutic Oncology","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84826890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-01DOI: 10.17303/jcrto.2021.9.205
SL Barton
{"title":"Osseous Metastases of Renal Epithelioid Angiomyolipoma with Dramatic Response Through mTOR Inhibitor Therapy","authors":"SL Barton","doi":"10.17303/jcrto.2021.9.205","DOIUrl":"https://doi.org/10.17303/jcrto.2021.9.205","url":null,"abstract":"","PeriodicalId":15189,"journal":{"name":"Journal of Cancer Research and Therapeutic Oncology","volume":"63 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79809176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-10-01DOI: 10.17303/jcrto.2021.9.204
F. Hongo
{"title":"Serum X Linked Inhibitor of Apoptosis Protein (XIAP) as a Biomarker for Predicting Recurrence of Low Grade Renal Cell Carcinoma","authors":"F. Hongo","doi":"10.17303/jcrto.2021.9.204","DOIUrl":"https://doi.org/10.17303/jcrto.2021.9.204","url":null,"abstract":"","PeriodicalId":15189,"journal":{"name":"Journal of Cancer Research and Therapeutic Oncology","volume":"2014 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73719817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.17303/jcrto.2021.9.202
Andrea Grego
{"title":"The Influence of Pre PARP-Inhibitor Platinum Chemotherapy in BRCA Mutated Ovarian Cancer, A Monocentric Experience","authors":"Andrea Grego","doi":"10.17303/jcrto.2021.9.202","DOIUrl":"https://doi.org/10.17303/jcrto.2021.9.202","url":null,"abstract":"","PeriodicalId":15189,"journal":{"name":"Journal of Cancer Research and Therapeutic Oncology","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84683332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.13189/cor.2021.070201
Kartiki Bhandari, Rupali R. Patil, P. Pingale, S. Amrutkar
Cancer has been one of the deadliest diseases for several decades and there is no precise and standard treatment option available up to date. Statistical data indicate that cancer has been one of the principal reasons for mortality worldwide. Although most of the novel techniques assist in the acceleration of cancer research, the available anticancer therapy does not exhibit expected success rates. This is due to a lack of understanding about the root cause of the disease, which can be accomplished by studying different types of tumors and the effects of various anti-cancer agents on the tumors. These studies require various in vitro study models which can mimic real, in vivo cancers. Conventional experimental models such as animal models, two-dimensional (2D) cell lines, patient-derived xenografts (PDX) are key models in cancer study but they have some shortcomings that are overcome by three-dimensional (3D), in-vitro tumor organoids derived from embryonic, induced pluripotent, or adult stem cells (ESCs, iPSCs, ASCs respectively). These organoid models closely recapitulate the original tumor present in vivo and thereby benefit in studying the development of cancer, efficacy, and safety of various anti-cancer agents, drug development, personalized therapy, low and high throughput screening. As a result, 3D organoids are becoming more successful experimental models over conventional 2D models. Therefore, this review emphasizes the effectiveness of organoid models in cancer study, their method of preparation, advantages and applications, drawbacks with solutions to address, followed by a brief outline on 4D organoids (assembloids), and future perspectives.
{"title":"Emphasis on Organoids in Cancer Research","authors":"Kartiki Bhandari, Rupali R. Patil, P. Pingale, S. Amrutkar","doi":"10.13189/cor.2021.070201","DOIUrl":"https://doi.org/10.13189/cor.2021.070201","url":null,"abstract":"Cancer has been one of the deadliest diseases for several decades and there is no precise and standard treatment option available up to date. Statistical data indicate that cancer has been one of the principal reasons for mortality worldwide. Although most of the novel techniques assist in the acceleration of cancer research, the available anticancer therapy does not exhibit expected success rates. This is due to a lack of understanding about the root cause of the disease, which can be accomplished by studying different types of tumors and the effects of various anti-cancer agents on the tumors. These studies require various in vitro study models which can mimic real, in vivo cancers. Conventional experimental models such as animal models, two-dimensional (2D) cell lines, patient-derived xenografts (PDX) are key models in cancer study but they have some shortcomings that are overcome by three-dimensional (3D), in-vitro tumor organoids derived from embryonic, induced pluripotent, or adult stem cells (ESCs, iPSCs, ASCs respectively). These organoid models closely recapitulate the original tumor present in vivo and thereby benefit in studying the development of cancer, efficacy, and safety of various anti-cancer agents, drug development, personalized therapy, low and high throughput screening. As a result, 3D organoids are becoming more successful experimental models over conventional 2D models. Therefore, this review emphasizes the effectiveness of organoid models in cancer study, their method of preparation, advantages and applications, drawbacks with solutions to address, followed by a brief outline on 4D organoids (assembloids), and future perspectives.","PeriodicalId":15189,"journal":{"name":"Journal of Cancer Research and Therapeutic Oncology","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84725305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-01DOI: 10.13189/COR.2021.070101
S. Kadam, Pradeep Tripathi, Tejaswini Kadam
Introduction : We are reporting a case of 18 year old boy who presented with features of lower respiratory tract infections and labelled as suffering from left suprarenal gland tumor. However, after complete evaluation, it is diagnosed as left retroperitoneal tumor extending into left thoracic cavity with involvement of left lower lobe lung. He underwent debulking surgery. Rhabdomyosarcoma (RMS) originates from immature striated muscle and it is considered as the most aggressive malignant mesenchymal tumor. The most common location of RMS is head and neck region. The retroperitoneal presentation of embryonal RMS is extremely rare. The four histological features of RMS, classified by WHO are embryonal, alveolar, pleomorphic and spindle cell or sclerosing. Pleomorphic RMS has worse prognosis. The incidence of embryonal tumors is higher in males with bimodal age distribution, between 2-6 years and second peak between 10-18 years. Their detection is incidental when the size is small and as the size enlarges, symptoms helps in detection. Due to its rarity at retroperitoneal location, there is a lack of literature over the adjuvant treatment. As the size enlarges at retroperitoneal region, enblock resection with clear margins becomes a difficult task and if planned for R0 resection, multiorgan resection escalates surgical morbidity rate. Conclusion : It is a rare location of embryonal rhabdomyosarcoma at retroperitoneal region with rare presentation of intra-thoracic infiltration. R0 resection is the principle goal of surgical excision of retroperitoneal sarcoma.
{"title":"A Rare Presentation of a Large Embryonal Rhabdomyosarcoma at Retroperitoneal Region with Intra-thoracic Extension & Misdiagnosed as Lower Respiratory Tract Infection: A Case Report","authors":"S. Kadam, Pradeep Tripathi, Tejaswini Kadam","doi":"10.13189/COR.2021.070101","DOIUrl":"https://doi.org/10.13189/COR.2021.070101","url":null,"abstract":"Introduction : We are reporting a case of 18 year old boy who presented with features of lower respiratory tract infections and labelled as suffering from left suprarenal gland tumor. However, after complete evaluation, it is diagnosed as left retroperitoneal tumor extending into left thoracic cavity with involvement of left lower lobe lung. He underwent debulking surgery. Rhabdomyosarcoma (RMS) originates from immature striated muscle and it is considered as the most aggressive malignant mesenchymal tumor. The most common location of RMS is head and neck region. The retroperitoneal presentation of embryonal RMS is extremely rare. The four histological features of RMS, classified by WHO are embryonal, alveolar, pleomorphic and spindle cell or sclerosing. Pleomorphic RMS has worse prognosis. The incidence of embryonal tumors is higher in males with bimodal age distribution, between 2-6 years and second peak between 10-18 years. Their detection is incidental when the size is small and as the size enlarges, symptoms helps in detection. Due to its rarity at retroperitoneal location, there is a lack of literature over the adjuvant treatment. As the size enlarges at retroperitoneal region, enblock resection with clear margins becomes a difficult task and if planned for R0 resection, multiorgan resection escalates surgical morbidity rate. Conclusion : It is a rare location of embryonal rhabdomyosarcoma at retroperitoneal region with rare presentation of intra-thoracic infiltration. R0 resection is the principle goal of surgical excision of retroperitoneal sarcoma.","PeriodicalId":15189,"journal":{"name":"Journal of Cancer Research and Therapeutic Oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83444645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-18DOI: 10.17303/jcrto.2021.9.103
{"title":"Patient Bone Marrow Aspiration to Explore the Cyclooxygenases (COXs) Involvement in Multiple Myeloma","authors":"","doi":"10.17303/jcrto.2021.9.103","DOIUrl":"https://doi.org/10.17303/jcrto.2021.9.103","url":null,"abstract":"","PeriodicalId":15189,"journal":{"name":"Journal of Cancer Research and Therapeutic Oncology","volume":"82 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88594969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：